MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 584227 | Name: Lobucavir

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Lobucavir, also known as Cyclobut-G, inhibits the replication of HIV virus in T cells, monocytes & macrophages in vitro by inhibiting DNA polymerase and viral DNA synthesis.

Chemical Structure

Lobucavir
Lobucavir
CAS#126062-18-8

Theoretical Analysis

MedKoo Cat#: 584227

Name: Lobucavir

CAS#: 126062-18-8

Chemical Formula: C11H15N5O3

Exact Mass: 265.1175

Molecular Weight: 265.27

Elemental Analysis: C, 49.81; H, 5.70; N, 26.40; O, 18.09

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Lobucavir; Cyclobut-G
IUPAC/Chemical Name
2-Amino-9-(2,3-bis(hydroxymethyl)cyclobutyl)-1,9-dihydro-6H-purin-6-one
InChi Key
GWFOVSGRNGAGDL-UHFFFAOYSA-N
InChi Code
InChI=1S/C11H15N5O3/c12-11-14-9-8(10(19)15-11)13-4-16(9)7-1-5(2-17)6(7)3-18/h4-7,17-18H,1-3H2,(H3,12,14,15,19)
SMILES Code
O=C1NC(N)=NC2=C1N=CN2C3C(CO)C(CO)C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 265.27 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: De Clercq E, Naesens L, De Bolle L, Schols D, Zhang Y, Neyts J. Antiviral agents active against human herpesviruses HHV-6, HHV-7 and HHV-8. Rev Med Virol. 2001 Nov-Dec;11(6):381-95. Review. PubMed PMID: 11747000. 2: Alrabiah FA, Sacks SL. New antiherpesvirus agents. Their targets and therapeutic potential. Drugs. 1996 Jul;52(1):17-32. Review. PubMed PMID: 8799682. 3: Christensen ND, Pickel MD, Budgeon LR, Kreider JW. In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. Antiviral Res. 2000 Nov;48(2):131-42. PubMed PMID: 11114415. 4: Hoffman VF, Skiest DJ. Therapeutic developments in cytomegalovirus retinitis. Expert Opin Investig Drugs. 2000 Feb;9(2):207-20. Review. PubMed PMID: 11060672. 5: Hebart H, Kanz L, Jahn G, Einsele H. Management of cytomegalovirus infection after solid-organ or stem-cell transplantation. Current guidelines and future prospects. Drugs. 1998 Jan;55(1):59-72. Review. PubMed PMID: 9463790. 6: Marques AR, Straus SE. Advances in the treatment of chronic hepatitis B virus infection. Rev Med Virol. 1998 Oct;8(4):223-234. PubMed PMID: 10398511. 7: Field AK, Tuomari AV, McGeever-Rubin B, Terry BJ, Mazina KE, Haffey ML, Hagen ME, Clark JM, Braitman A, Slusarchyk WA, et al. (+-)-(1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)-cyclobutyl] guanine [(+-)-BHCG or SQ 33,054]: a potent and selective inhibitor of herpesviruses. Antiviral Res. 1990 Jan;13(1):41-52. PubMed PMID: 2159261. 8: Yang H, Drain RL, Franco CA, Clark JM. Efficacy of BMS-180194 against experimental cytomegalovirus infections in immunocompromised mice. Antiviral Res. 1996 Mar;29(2-3):233-41. PubMed PMID: 8739602. 9: Hu N, Shiota H. Emergence of resistance to carbocyclic oxetanocin G in herpes simplex virus type 1 and genetic analysis of resistant mutants. Acta Pharmacol Sin. 2004 Jul;25(7):921-6. PubMed PMID: 15210066. 10: Ying C, De Clercq E, Nicholson W, Furman P, Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat. 2000 Mar;7(2):161-5. PubMed PMID: 10760047. 11: Berenguer M, Wright TL. Hepatitis B and C viruses: molecular identification and targeted antiviral therapies. Proc Assoc Am Physicians. 1998 Mar-Apr;110(2):98-112. Review. PubMed PMID: 9542765. 12: Darses B, Greene AE, Poisson JF. Asymmetric synthesis of cyclobutanones: synthesis of cyclobut-G. J Org Chem. 2012 Feb 17;77(4):1710-21. doi: 10.1021/jo202261z. Epub 2012 Jan 26. PubMed PMID: 22283963. 13: Terry BJ, Cianci CW, Hagen ME. Inhibition of herpes simplex virus type 1 DNA polymerase by [1R(1 alpha,2 beta,3 alpha)]-9-[2,3-bis(hydroxymethyl)cyclobutyl] guanine. Mol Pharmacol. 1991 Oct;40(4):591-6. PubMed PMID: 1656194. 14: Yang Z, Manitpisitkul P, Sawchuk RJ. In situ studies of regional absorption of lobucavir and ganciclovir from rabbit intestine and predictions of dose-limited absorption and associated variability in humans. J Pharm Sci. 2006 Oct;95(10):2276-92. PubMed PMID: 16883564. 15: Yamanaka G, Tuomari AV, Hagen M, McGeever-Rubin B, Terry B, Haffey M, Bisacchi GS, Field AK. Selective activity and cellular pharmacology of (1R-1 alpha,2 beta,3 alpha)-9-[2,3-bis(hydroxymethyl)cyclobutyl]guanine in herpesvirus-infected cells. Mol Pharmacol. 1991 Sep;40(3):446-53. PubMed PMID: 1896029. 16: Ying C, Van Pelt J, Yap SH, De Clercq E, Neyts J. Use of digoxigenin-labelled probes for the quantitation of HBV-DNA in antiviral drug evaluation. J Virol Methods. 1999 Aug;81(1-2):155-8. PubMed PMID: 10488773. 17: Yamanaka G, Wilson T, Innaimo S, Bisacchi GS, Egli P, Rinehart JK, Zahler R, Colonno RJ. Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother. 1999 Jan;43(1):190-3. PubMed PMID: 9869593; PubMed Central PMCID: PMC89048. 18: Zhang Y, Schols D, De Clercq E. Selective activity of various antiviral compounds against HHV-7 infection. Antiviral Res. 1999 Aug;43(1):23-35. PubMed PMID: 10480261. 19: Reusser P. Current concepts and challenges in the prevention and treatment of viral infections in immunocompromised cancer patients. Support Care Cancer. 1998 Jan;6(1):39-45. Review. PubMed PMID: 9458535. 20: Braitman A, Swerdel MR, Olsen SJ, Tuomari AV, Lynch JS, Blue B, Michalik T, Field AK, Bonner DP, Clark JM. Evaluation of SQ 34,514: pharmacokinetics and efficacy in experimental herpesvirus infections in mice. Antimicrob Agents Chemother. 1991 Jul;35(7):1464-8. PubMed PMID: 1656863; PubMed Central PMCID: PMC245191.